| Autor: |
Neltner TJ; Department of Nutrition and Health Sciences, University of Nebraska- Lincoln, Lincoln, NE, USA., Sahoo PK; Department of Nutrition and Health Sciences, University of Nebraska- Lincoln, Lincoln, NE, USA., Smith RW; Department of Nutrition and Health Sciences, University of Nebraska- Lincoln, Lincoln, NE, USA., Anders JPV; Department of Human Sciences, Ohio State University, Columbus, OH, USA., Arnett JE; Department of Nutrition and Health Sciences, University of Nebraska- Lincoln, Lincoln, NE, USA., Schmidt RJ; Department of Nutrition and Health Sciences, University of Nebraska- Lincoln, Lincoln, NE, USA., Johnson GO; Department of Nutrition and Health Sciences, University of Nebraska- Lincoln, Lincoln, NE, USA., Natarajan SK; Department of Nutrition and Health Sciences, University of Nebraska- Lincoln, Lincoln, NE, USA., Housh TJ; Department of Nutrition and Health Sciences, University of Nebraska- Lincoln, Lincoln, NE, USA. |
| Abstrakt: |
Type 1 collagen is an abundant structural protein with importance to the skin, eyes, bones, ligaments, tendons, and muscles. Shilajit supplementation has been shown to increase gene expression of collagen synthesis, however, it is unclear if increased gene expression translates to increases in circulating levels. Therefore, the purpose of the present study was to examine the effects of 8 weeks of daily supplementation with 500 mg·d -1 and 1000 mg·d -1 of Shilajit versus placebo on serum pro-c1α1, a biomarker of type 1 collagen synthesis. Thirty-five recreationally trained men (mean ± SD: age = 21.1 ± 1.8 yrs; body mass = 80.7 ± 12.4 kg; height = 180.9 ± 6.7 cm) volunteered to participate in this study. Mixed factorial and one-way ANOVAs were used to analyze mean differences between groups, with follow-up t-tests when necessary. Individual subject responses were assessed using the minimal clinically important difference and Chi-squared tests. There were significant (Low dose: p = 0.008, d = 1.2; High dose: p = 0.007, d = 1.3) increases in serum pro-c1α1 from pre- (Low dose: 42.5 ± 12.4 ng·mL -1 ; High dose: 42.7 ± 12.7 ng·mL -1 ) to post-supplementation (Low dose: 82.3 ± 46.5 ng·mL -1 ; High dose: 113.1 ± 78.7 ng·mL -1 ) for the low and high dose groups, however, no change ( p > 0.05) for the placebo group. A greater proportion ( p = 0.03) of subjects exhibited increases in pro-c1α1 that exceeded the minimal clinically important difference in the high dose Shilajit group (75%) compared to the placebo group (30%), but no differences ( p = 0.06) between the low dose Shilajit group (69%) and placebo. In conclusion, 8 weeks of Shilajit supplementation with 500 and 1000 mg·d -1 increased type 1 collagen synthesis as indicated by serum levels of pro-c1α1. |
